Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).Mirum’s late-stage pipeline includes three investigational treatments for debilitating liver diseases. The LIVMARLI development program includes the Phase 2b EMBARK study for biliary atresia. Mirum’s second investigational IBAT inhibitor is volixibat, which is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, Chenodal, is being evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.

Oberland Capital

New Enterprise Associates

Chiesi Ventures

Deerfield Capital Management

Frazier Healthcare Partners

RiverVest

Rock Springs Capital

Novo Holdings

Pappas Capital

Mirum Pharmaceuticals, Inc.

Akero Therapeutics is a biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases.

Akero

GENFIT is a biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases.

GENFIT

Cyta Therapeutics is a biopharmaceutical company dedicated to developing novel therapies for liver diseases, with a focus on innovative treatment approaches.

Cyta Therapeutics, Inc.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutic options for cardiovascular and metabolic diseases.

Madrigal Pharmaceuticals Inc

Fulcrum Therapeutics is a biopharmaceutical company focused on developing new medicines to deliver transformative therapies for genetically defined diseases.

Fulcrum Therapeutics

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for debilitating rare and orphan diseases. Their pipeline products include LIVMARLI (maralixibat) Oral Solution and Volixibat, targeting various liver diseases.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Mar 5, 2024 4:27 AM	27b2479c
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 4:27 AM	21fe1237
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
peers	general
news basic	general	Mar 5, 2024 4:27 AM	945e710f
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis	Sep 29, 2024 6:40 AM	1b298dd8
funding rounds analysis	company_analysis
company structure	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:MIRUMPHARMA

Mirum Pharmaceuticals Inc

Last Close

39.18

31/10 18:09

Market Cap

1.69B

Beta: -

Volume Today

67.61K

Avg: -